Results 61 to 70 of about 364,936 (336)
Inhibition of Classical and Alternative Complement Pathway by Ravulizumab and Eculizumab
ABSTRACT Objective To explore the feasibility of classical (CH50) and alternative (AH50) complement pathway activity as potential biomarkers for treatment guidance and monitoring during therapy with ravulizumab in patients with generalized myasthenia gravis (gMG) and compare these to therapeutic drug monitoring under eculizumab.
Lea Gerischer +14 more
wiley +1 more source
Immunogenicity of autoantigens [PDF]
Autoantibodies against self-antigens have been associated not only with autoimmune diseases, but also with cancer and are even found in healthy individuals. The mechanism causing the autoantibody response remains elusive for the majority of the immunogenic antigens. To deepen the understanding of autoantibody responses, we ask whether natural-occurring,
Keller Andreas +7 more
openaire +3 more sources
Lipid nanoparticles (LNPs) are optimized to co‐deliver Cas9‐encoding messenger RNA (mRNA), a single guide RNA (sgRNA) targeting the endogenous cystic fibrosis transmembrane conductance regulator (CFTR) gene, and homologous linear double‐stranded donor DNA (ldsDNA) templates encoding CFTR.
Ruth A. Foley +12 more
wiley +1 more source
Pregnancy has a minimal impact on the acute transcriptional signature to vaccination. [PDF]
Vaccination in pregnancy is an effective tool to protect both the mother and infant; vaccines against influenza, pertussis and tetanus are currently recommended.
Aerssens, A +10 more
core +1 more source
Chimeric antigen receptor-engineered T cell therapies (CAR-T) are becoming powerful immunotherapeutic tools for treating malignancies, especially hematological malignancies.
Hammodah R. Alfar +5 more
doaj +1 more source
Cytokine immunogene therapy [PDF]
The prognosis for patients with either a primary or metastatic brain tumor is poor. Clearly new forms of therapy to improve the long-term survival of patients with malignant brain tumors are urgently needed. The authors are in the process of developing a new and novel form of treatment for primary and metastatic brain tumors in which they use genes ...
R P, Glick, T, Lichtor, E P, Cohen
openaire +2 more sources
Bloodstream infections (BSI) are one of the leading causes of mortality and morbidity in both civilian and military populations. This paper summarizes recent progress in novel treatment strategies to manage BSI arising from both bacterial and fungal pathogens using molecules, particles, and materials to elicit host‐directed immunity.
Thomas Thomou +11 more
wiley +1 more source
Analogue peptides for the immunotherapy of human acute myeloid leukemia [PDF]
Accepted manuscript. The final publication is available at: http://link.springer.com/article/10.1007%2Fs00262-015-1762-9The use of peptide vaccines, enhanced by adjuvants, has shown some efficacy in clinical trials.
A Driessche Van +102 more
core +2 more sources
The European Immunogenicity Platform (EIP) celebrated the 15th edition of its Open Symposium on Immunogenicity of Biopharmaceuticals and its associated one-day workshop on 22–24 February 2024 in Lisbon.
Sophie Tourdot +39 more
doaj +1 more source
Self‐Immolative Activatable Nanoassembly toward Immuno‐Photodynamic Therapy in TME
A quinone methide‐gated, self‐immolative, H2O2‐responsive nano‐photosensitizer (Pyz/PS) is developed for targeted immuno‐photodynamic therapy. Pyz/PS selectively activates within tumor microenvironments, restores photosensitizer activity, generates ROS, and depletes intracellular GSH, enhancing oxidative stress.
Jing Li +10 more
wiley +1 more source

